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a  b  s  t  r  a  c  t
Heart  failure (HF)  occurs  across  the  entire  range  of left  ventricular  (LV)  ejection  fractions  (EF),  not  just
reduced  EF.  Nearly  half  or  more  patients  presenting  with  HF  have  a  preserved  EF  > 0.50  (HFpEF).  Diastolic
dysfunction  is  apparent  in  all patients  with  HF,  regardless  of  EF.  A preserved  EF  indicates  that  the end-eywords:
jection fraction
eart failure
eart failure with preserved ejection
raction
diastolic  volume  is  appropriate  for the  stroke  volume,  and  a  reduced  EF  indicates  that  the  end-diastolic
volume  is  enlarged  relative  to stroke  volume  (i.e.  the  LV  is  dilated).  Most  therapies  proven  to be effec-
tive  in  HF with  a reduced  EF  (ACE-inhibitors,  angiotensin  receptor  blockers,  beta-blockers,  and  cardiac
resynchronization)  reverse  LV  dilation.  These  therapies  have  not  been  proven  to  be  effective  in  HFpEF.
Increasing  c-GMP  may be  a  treatment  target  in HFpEF,  and  potential  ways  of increasing  c-GMP  are  being
studied.  Finally,  comorbidities  are  important  in HFpEF  and  are  additional  targets  for therapy.
© 2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ontents
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ntroduction
Twenty-ﬁve years ago, heart failure (HF) was understood as a
linical syndrome due to left ventricular (LV) systolic dysfunction
pparent as reduced ejection fraction (EF) [1]. Finding a reduced EF
n a patient with clinical signs and symptoms of HF provides objec-
ive documentation of cardiac dysfunction, thus making it almost
ertain that the patient does indeed have HF. Based on this under-
tanding, large randomized trials were conducted using an EF < 0.30
r 0.35 as a key entry criterion. These studies demonstrated that
associated with reversal of the LV dilation (eccentric remodeling)
present in HFrEF [3]. In contrast, the use of positive inotropic agents
to improve systolic function were either of no beneﬁt or actually
detrimental in HFrEF [2]. This suggested that there was more to HF
than just systolic dysfunction. The concept that all HF was due to
systolic dysfunction apparent as a reduced EF was  challenged by the
subsequent recognition that HF occurs in patients with the entire
range of EFs, including EF > 0.50, an EF that is in the normal or near
normal range (i.e. preserved EF > 0.50) [4]. It is now recognized that
as many as half or more patients with HF have preserved EF (HFpEF).he use of angiotensin-converting enzyme inhibitors, angiotensin
eceptor blockers, beta-adrenergic blockers, aldosterone blockers,
nd cardiac resynchronization improved morbidity and mortality
n patients with HF and a reduced EF (HFrEF) [2]. The beneﬁt
f these interventions (except for aldosterone blockade) was
 Parts of this review are derived from Little WC,  Zile MR. HFpEF: cardiovascular
bnormalities not just co-morbidities. Circ Heart Fail 2012;5:669–71.
∗ Corresponding author at: Cardiology Section, Wake Forest School of Medicine,
edical Center Boulevard, Winston-Salem, NC 27157-1045, USA.
el.: +1 336 716 4342; fax: +1 336 716 5324.
E-mail address: wlittle@wakehealth.edu (W.C. Little).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.02.017The systolic function of the LV can be considered as its ability
to generate pressure and empty producing the stroke volume [5].
The LVEF, which is the ratio of stroke volume to LV end-diastolic
volume, is the standard clinical measurement of systolic function.
A normal EF indicates that the stroke volume is appropriate for
the end-diastolic volume and vice versa. In a patient with acute
cardiogenic shock following a large myocardial infarction, the EF is
reduced due to a low stroke volume, while the end-diastolic volume
is normal. In contrast, in stable patients (i.e. functional class 1, 2,
or 3) with HFrEF the stroke volume is normal or near normal, and
the EF is reduced because the end-diastolic volume is increased [6].
Thus, the reduction in EF indicates that the LV end-diastolic volume
vier Ltd. All rights reserved.
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s increased relative to the stroke volume. Thus, the EF is not just a
easure of systolic function but, in the absence of shock, is also a
ensitive index of LV remodeling.
Many features of the HF syndrome are similar across the EF spec-
rum including: elevated left atrial pressure, abnormal LV ﬁlling
ynamics, neuro-hormonal activation, dyspnea, impaired exer-
ise tolerance, frequent hospitalization and re-hospitalization, and
educed survival [7,8]. It is important to recognize that almost all
atients with HF regardless of EF have diastolic LV abnormalities,
specially of long-axis diastolic velocity [6]. Further, patients with
FpEF have both systolic and diastolic long-axis dysfunction.
There are also clear clinical differences between HFpEF and
FrEF. Patients with HFpEF are older, are more likely to be women,
here is a strong association with systolic hypertension, and these
atients are less likely to have myocardial ischemia. In addition,
here are differences in cardiac structure and function [9,10]. In
FrEF the LV is dilated with eccentric remodeling. In contrast, the
V end-diastolic volume is not increased relative to the stroke vol-
me  in HFpEF, and concentric remodeling (with or without LV
ypertrophy) is present in some patients. In addition, in HFrEF, LV
ystolic elastance is reduced and arterial elastance is elevated so
hat there is impaired ventricular–vascular coupling. In contrast,
oth LV and arterial elastance are increased in HFpEF so that the
oupling between them is preserved [11,12]. In fact, the presence
f a normal EF indicates that the coupling of the LV and arterial
ystem is nearly optimal to convert the energy of contraction into
he stroke work [13,14]. Thus, arterial vasodilation improves LV
ystolic performance in HFrEF, but not in HFpEF [15].
There are also clear differences in the response to treat-
ent between HFrEF and HFpEF. Large randomized, multicenter,
lacebo-controlled, double-blind trials have been conducted in
atients with HFrEF. These trials demonstrated that mortality
nd morbidity in HFrEF are reduced by: angiotensin-converting
nzyme inhibitors, beta-adrenergic blockers, angiotensin II recep-
or blockers, aldosterone blockers, and cardiac resynchronization
ith biventricular pacing [2]. In contrast, these interventions either
ave not shown similar beneﬁt in HFpEF or have not been studied.
here have been four large trials studying the effects of ther-
py on HFpEF: Dig Sub-Study, CHARM Preserved, PEP-CHF, and
-PRESERVE. The Dig Sub-Study found no effect of digoxin on
otal mortality or all-cause hospitalization in patients with sta-
le HFpEF and normal sinus rhythm (EF > 0.45) [16]. The CHARM
reserved Trial compared the angiotensin receptor blocker, can-
esartan, with placebo in HF patients with an EF > 40%. There was
nly a small reduction in cardiovascular death and HF hospitaliza-
ion of borderline signiﬁcance and no reduction in mortality [17].
he PEP-CHF trial compared the angiotensin-converting enzyme
nhibitor, perindopril, and placebo in HF patients aged ≥70 years
ith an EF > 45%. There was no reduction in mortality and HF hos-
italization [18]. Similarly, the I-PRESERVE study found that the
ngiotensin receptor blocker, irbesartan, had no effect on cardio-
ascular mortality and hospitalization in patients with HF and an
F > 45% [19]. There has been no large randomized trial of beta-
lockers in HFpEF. However, the extensive OPTIMISE-HF registry
ound that beta-blocker therapy did not improve survival in HFpEF
atients, but did enhance survival in patients with HFrEF [20]. Thus,
herapies proven to improve outcome in HFrEF, which are associ-
ted with reversal of LV dilation, have not been demonstrated to
e effective in patients with HFpEF [2,11]. In retrospect, this should
ot have been unexpected since patients with HFpEF do not have
V dilation.
There are several studies being planned or underway for other
reatment approaches to HFpEF, one of which is a large study of
he aldosterone blocker, spironolactone [21]. This agent improved
utcome in HFrEF without reversing LV dilation. In addition, there
re several studies using three potential approaches to enhancingCardiology 62 (2013) 1–3
cyclic guanine cyclase utilizing agents that preliminary studies
suggested might be effective. For example, a small single-center
study suggested that the PDE-5 inhibitor, sildenaﬁl, improves dia-
stolic function and exercise tolerance in patients with HFpEF and
associated pulmonary hypertension [22]. A large multicenter study
of sildenaﬁl is underway [23]. Similarly, a large trial will be start-
ing soon of a neprilysin inhibitor, which showed a signal of the
beneﬁt in HFpEF in a small study [24]. Finally, two large ran-
domized trials have found that statins have no beneﬁt in patients
with HFrEF [25,26]. However, an observational study suggests that
statins may  be beneﬁcial in patients with HFpEF [27]. A large multi-
center placebo-controlled study of statins in HFpEF is being planned
in Europe.
Although both HFpEF and HFrEF frequently have important
comorbidities, the impact of comorbidities may be more profound
in patients with HFpEF [28,29] which include: hypertension, obe-
sity, diabetes, and sleep apnea. These comorbidities are important
drivers of hospitalization in these patients [30]. Thus, aggressive
management of these comorbidities may  improve the outcome in
HFpEF; however, HFpEF is more than a collection of comorbidities
[31]. Therefore, while treatment of comorbidities may delay or pre-
vent the development of HFpEF, it may  not be adequate treatment
for all patients.
Conclusions
The understanding of HF has evolved beyond the previous naïve
concept that it was solely due to systolic dysfunction, apparent as a
reduced EF. Although, we  have effective proven therapy for HFrEF,
for many patients with HFpEF, there is no proven therapy. Presently,
management of HFpEF consists of treating the frequent comorbidi-
ties. Studies are being planned or underway to investigate new
approaches to treatment.
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